At least the newsletter came. Perhaps I was confused about PW...

At least the newsletter came. Perhaps I was confused about PW stating we would get XP results by year end but certainly the earlier newsletters estimated by end 2022. PW now states January and I guess he is limited by external parties collating the results. Can't contemplate the results not looking good as this undermines the whole OTC product launch (at least the melanogenic lines). There's a lot to look forward to and EPP expansion and increasing sales is one he doesn't mention. Continued growth in revenues will be needed to lift valuations but also underpin expenditure going forward. I wish the SP was higher but it's hanging in there at the moment despite the volatility in markets. Seems like the volatility will continue at least to mid 2023. I think positive results in stroke will also be pivotal to value and, given it's outside their original business model of photoprotection, what a bonus. Leading into 2024 with ACTH and potential for neuro muscular indications to follow. Plenty to look forward to if they execute. Merry Xmas GLTA